Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Cognition Disorders: early-phase trial registry

A small indexed set (10 trials) with no open enrollment listed right now.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count

Cognition Disorders: 10 US clinical trials tracked, none currently recruiting.

Cognition Disorders is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is US Department of Veterans Affairs, running 2 of these trials.

Enrollment posture brief

Registry condition cognition-disorders

OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #1724 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Cognition Disorders (this)0%
Open-enrollment share among volume-matched conditions near Cognition Disorders

Cognition Disorders has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cognition Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cognition Disorders is recruiting below its size-band peers.

    0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cognition Disorders research.

    US Department of Veterans Affairs accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cognition Disorders enrolment sits around 221 participants.

    Median target enrolment is 221 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.

  4. Cognition Disorders splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING 826 participants

The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors

Vanderbilt University Medical Center

NCT00392795

COMPLETED 538 participants

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study

University of Southern California

NCT02488720

COMPLETED 300 participants

Cognitive Problems in Veterans With Heart Failure

US Department of Veterans Affairs

NCT01049308

COMPLETED 230 participants

PET Scan to Map the Areas of the Brain Involved in Planning

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00001363

COMPLETED Phase 3 221 participants

Therapy for Depressed Elders With Thought Problems

University of Washington

NCT00052091

COMPLETED Phase 2 150 participants

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

Cognition Pharmaceuticals

NCT00529581

COMPLETED NA 128 participants

Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder

US Department of Veterans Affairs

NCT01040858

COMPLETED Phase 1 55 participants

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

University of Southern California

NCT02850146

COMPLETED NA 29 participants

Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x)

Stanford University

NCT01536977

COMPLETED Phase 1 6 participants

A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).

National Institute of Mental Health (NIMH)

NCT00000393

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Cognition Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

educational intervention Behavioral
1 trials
cognitive assessment Behavioral
1 trials
management of therapy complications Behavioral
1 trials
Placebo comparison group Other
1 trials
Cognitive Strategy Training Behavioral
1 trials
C105 Drug
1 trials
Brief Supportive Therapy Behavioral
1 trials
Peptide T Drug
1 trials

US sites by state

Facility locations filed on Cognition Disorders trials. A trial with sites in several states counts in each.

California 7 trials
New York 3 trials
Florida 3 trials
Connecticut 3 trials
Arizona 3 trials
Kansas 2 trials
Georgia 2 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cognition Disorders page

10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cognition Disorders condition card totals 10 registered trials; most-linked intervention educational intervention; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.